ESI-GROUP
20.10.2020 14:35:10 CEST | Business Wire | Press release
Launched in February 2020, the AMPLI project simulation, supported by the EIT Manufacturing and reuniting a consortium of five partners – ESI Group (Paris:ESI), coordinator of the project, Whirlpool, IPC (Innovation Plasturgie Composites), ENSAM and LMS (Laboratory for Manufacturing Systems & Automation) – will combine advantages of simulation and augmented reality to provide manufacturing workers with real-time knowledge and information. The project will bring an important step forward the digital transformation of European factories.
The plastics industry has already introduced enabling technologies to achieve zero-defect manufacturing and improve work cells flexibility such as in-mold sensors, in-line quality control, autonomous devices or predictive models. Augmented Reality (AR) offers new ways to interact not only with machines but also with manufacturing and product models. However, for further adoption, existing AR tools are still not specific enough to be relevant and need to offer dedicated platforms regarding each industrial domain.
The objective of the AMPLI project is to provide machine operators with real-time knowledge and information to improve decision-making and working procedures thanks to the development of an AR tool dedicated to the manufacturing value chain of polymer forming process. The AR tool will be based on the combination of plastic domain-based knowledge (from tuning, production and maintenance) and the integration of numerical simulation.
AMPLI project target 3 main benefits:
-
Improve manufacturing efficiency
- time reduction for tuning a work cell: -10%
- increase machinery availability by preventive maintenance: +8%
- reduction of training period of work force: -25%
- reduction of scraps: -10%
- Eliminate skill shortages by capturing and return process knowledge
- Increase attractivity of shop floor work by fostering the use of digital tools, which is appealing for young people. Work becomes more visual, accessibility increases and facilitates the training
AMPLI project approach is to embed and enable physically realistic virtual objects in a real environment to be interactive. It is based on the improvement of AR mechanisms and usability through:
- embedded process simulation results thanks to reduced order model
- customized plastic and composite processing interface by mixing measured information coming from the manufacturing work cell and information coming from models
The project is sponsored by the EIT Manufacturing (European Institute of Innovation & Technology) and is supported by a consortium of 5 European partners led by ESI Group. Together, and for a period of one year, the consortium partners will be working on developing, testing and validating AR and simulation technology dedicated to a thermoforming process.
ESI will be the integrator of the final output based on existing AR tool. This step will be particularly challenging and key as AR need real-time information to be efficient which will not be possible without ESI’s expertise and innovation technologies like its model-order reduction platform. IPC will provide knowledge rules regarding setting and supervision. They will use their skills in machine interoperability and process control as guidance for the project. Moreover, IPC simulates currently thermoforming process using ESI software PAM-FORM.
LMS has extensive experience in developing AR application for the manufacturing domain to support different steps of the lifecycle. Among other AR apps, LMS has developed an AR solution to support the maintenance phase of injection molds.
ENSAM will develop AR features to mix manufacturing process simulation with reality.
Whirlpool as plastic converter will provide requirements and a pilot case dedicated to thermoforming to test and validate the product at an industrial scale.
AMPLI will bring to the market a new product with AR integrating both plastic domain knowledge and simulation as differentiator.
In mid-term, such benefits will be transferred to other manufacturing processes.
Project title
: Augmented Mold for setting and supervision of PLastIc product manufacturing
Project Duration:
12 months
Project Consortium:
ENSAM, ESI Group, IPC, LMS, Whirlpool
About ESI
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation.
Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists. In 2019, its proforma turnover was 146.2M€. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com .
Follow ESI
LinkedIn / Facebook / Twitter / Youtube
About the EIT & EIT Manufacturing
The European Institute of Technology and Innovation (EIT) is a body of the European Union and is an integral part of the Horizon 2020 program. EIT was established to support the innovators to change their best ideas to products, services and job positions for Europe. EIT consists of 8 Knowledge and Innovation Communities: EIT Manufacturing, EIT Climate-KIC, EIT Digital, EIT Food, EIT Health, EIT InnoEnergy, EIT RawMaterials, and EIT Urban Mobility.
EIT Manufacturing’s main goal is to bring European stakeholders focused on manufacturing together in innovation ecosystems that add unique value to European products, processes and services and inspire the creation of globally competitive and sustainable manufacturing. EIT Manufacturing associates more 50 organizations (universities, research institutes and business), such as Volkswagen, Volvo, Darmstadt University of Technology, the French Alternative Energies and Atomic Energy Commission (CEA), Siemens, Slovak University of Technology in Bratislava, Phillips, Procter & Gamble, and Whirlpool Europe to name a few.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005720/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
